HER2+ Breast Cancer Management: Navigating GnRH Agonist Choice and Patient Experience

EP: 1.Optimizing Therapy in HR+/HER2+ Breast Cancer: Balancing Endocrine, HER2-Targeted, and Chemotherapy Options

EP: 2.Treatment Planning for HER2+ Breast Cancer: The Role of Ovarian Function Suppression

Now Viewing

EP: 3.HER2+ Breast Cancer Management: Navigating GnRH Agonist Choice and Patient Experience

EP: 4.Navigating Early-Line Treatment Options for HER2+ Metastatic Breast Cancer

Video content above is prompted by the following: GnRH Agonists for Ovarian Suppression

Key Themes:

• Comparison between GnRH agonists
• Different GnRH agonists (leuprolide, goserelin) are equally efficacious at reducing ovarian function

• Practical differences include needle size and administration method

• NCCN guidelines updated to include both monthly and 3-month formulations
• Monitoring ovarian suppression
• Importance of following hormone levels to ensure efficacy

• In SOFT/TEXT trial, approximately 17% of patients had breakthrough ovulation at one year

• Experts recommend following interval levels for at least the first 12 months
• Age-related considerations
• Different approaches suggested for younger patients (<35) vs those approaching menopause

• Younger patients may benefit from monthly dosing initially to ensure suppression

• Transitioning perimenopausal patients off injections requires careful monitoring

Notable Insights:

• Dr Vidal noted: “The younger patients, because we think they have more robust estrogen production, I think I tend to keep them more on the monthly dosing and only transition after a while.”

Dr McCann suggested: “Those are also patients that I might refer to a gynecologist for removal of their ovaries, too. So that then you know for certain that they’re postmenopausal, and it gets them away from the shot.”